Description of Collaborative Activity: |
The objective of this initiative is for NLM to assist the FDA in indexing the content of structured product labels (SPL) for drugs. Natural language processing is used to extract drug-drug interaction information from SPLs that are validated by FDA. Transforming the narrative text to structured information encoded in national standard terminologies is a prerequisite to the effective deployment of drug safety information in drug labels for clinical decision support. The goals of the initial agreement were to develop optimal MetaMap settings for extracting Adverse Reactions (ARs) from SPLs and provide FDA with the software necessary to replicate the results. To evaluate the extraction quality, LHC and FDA developed a test collection of SPLs annotated with ARs. Annotation guidelines were developed. The collaboration goals are to conduct a community-wide evaluation of the available AR extraction tools. The evaluation venue is NIST Text Analysis Conference (TAC). Over 130 new labels were annotated with DDIs in FY18. |
